Novel Therapeutics: Sheba Inks Collaborative Agreement with Regeneron

October 27, 2022

Sheba Medical Center announced a collaboration agreement with Regeneron, a leading global biotechnology company, that will focus on oncology research and accelerating the development of potential novel therapeutics to help patients in need.

Regeneron will also sponsor Sheba’s ARC (Accelerate, Redesign and Collaborate) innovation center, where a “personalized medicine” development hub is creating cutting-edge solutions for patient care, and where Regeneron will join Sheba’s HealthTech Valley, a growing global ecosystem focusing on redesigning healthcare by bringing together academia, industry and medicine.

Founded and led for nearly 35 years by physician-scientists, Regeneron’s unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development, almost all of which were homegrown in Regeneron’s laboratories.

“The Regeneron team is pleased to collaborate with Sheba in order to accelerate clinical studies of novel oncology therapeutics for patients in need,” said David Weinreich, M.D., Executive Vice President, Global Clinical Development of Regeneron. “As we work to turn innovative science into needed medicines, we will partner with centers of excellence like Sheba that have established best practice clinical trial processes. We will also share knowledge through programs such as our joint Post-Doctoral Research program, because we know that fighting cancer requires cooperation from the best minds around the world.”

“We are excited and proud to partner with Regeneron to accelerate clinical research and to enhance patient access to novel treatments. The agreement exemplifies our mutual desire to improve patient outcomes with an emphasis on creating a better quality of life,” added Professor Yitshak Kreiss, Director General of Sheba Medical Center.